Octreotide used for probing the type-II' β-turn CD and Raman markers

Belén Hernández1, Yves-Marie Coïc, Sergei G Kruglik

  • 1Groupe de Biophysique Moléculaire, UFR Santé-Médecine-Biologie Humaine, Université Paris 13, Sorbonne Paris Cité, 74 rue Marcel Cachin, 93017 Bobigny Cedex, France.

Insights

Octreotide, a somatostatin analogue, transitions from disordered to ordered structures in aqueous solutions with increasing concentration. This study identifies specific spectroscopic markers for its type-II

Area of Science:

  • Biochemistry
  • Structural Biology
  • Medicinal Chemistry

Background:

  • Octreotide, a somatostatin (SST) analogue, is a key antiproliferative drug for endocrine tumors.
  • Previous studies in organic solvents indicated a type-II' β-turn structure for octreotide.
  • Limited systematic analysis existed for octreotide's structural behavior in aqueous solutions.

Purpose of the Study:

  • To synthesize and purify octreotide for optical spectroscopic analysis.
  • To systematically analyze octreotide's structural behavior in aqueous solution.
  • To identify specific spectroscopic markers for the type-II' β-turn structure using octreotide as a model.

Main Methods:

  • Chemical synthesis and purification of octreotide.
  • Circular Dichroism (CD) spectroscopy across a concentration range (25-250 μM).
  • Raman spectroscopy across a concentration range (1-20 mM).

Main Results:

  • Octreotide exhibits a concentration-dependent transition from disordered to ordered structures in aqueous solution.
  • Characteristic CD markers for the β-turn were identified above 50 μM (negative band at ~202 nm, shoulder at ~218 nm).
  • Raman spectroscopy assigned specific amide I (~1678, ~1650 cm⁻¹) and amide III (~1303, ~1288, ~1251 cm⁻¹) bands to the type-II' β-turn.

Conclusions:

  • Established specific CD and Raman spectroscopic signatures for the type-II' β-turn in octreotide.
  • Confirmed the stability of the antiparallel β-sheet structure via disulfide bridge analysis.
  • Provided a foundation for understanding structural differences between somatostatin-14 and octreotide.